Πληροφορίες από MoonbeamNetwork(@MoonbeamNetwork)

There is some notable progress emerging in the landscape of COVID-19 therapeutics. Traws Pharma is currently developing Ratutrelvir, a novel anti-SARS-CoV-2 antiviral intended to function as a potential substitute for Paxlovid.
The organization has successfully wrapped up enrollment for its Phase 2 clinical trial, with interim data suggesting the treatment provides a benefit. This development is particularly encouraging for patients who are unable to tolerate Paxlovid. Unlike its competitor, Ratutrelvir is formulated without ritonavir, thereby avoiding the safety issues and side effects frequently associated with that compound.
Links in next (1/2)

.css-1iqe90x{box-sizing:border-box;margin:0;min-width:0;color:#EAECEF;}There is some notable progress emerging in the landscape of COVID-19 therapeutics. Traws Pharma is currently developing Ratutrelvir, a novel anti-SARS-CoV-2 antiviral intended to function as a potential substitute for Paxlovid.

There is some notable progress emerging in the landscape of COVID-19 therapeutics. Traws Pharma is currently developing Ratutrelvir, a novel anti-SARS-CoV-2 antiviral intended to function as a potential substitute for Paxlovid.